ForumIAS LATEST
- 04 June | MGP Strategy Series | GS Paper 4 (Ethics) with AIR 7 A.R. Rajah Mohaideen Click Here to register for the session →
- 04 June | GS Advance Program begins from 4th June 2026 | First 2 classes open to all Click Here to register for the event →
- 05 June | MGP Strategy Series | GS Paper 3 Strategy Session with AIR 406 Mannat Luthra Click Here to register for the session
- 06 June | Open Orientation on Essay Guidance Program (EGP 2026) Click Here to register →
- 07 June | Open Orientation for Current Affairs for Mains 2026 Click Here to register →
- 07 June | Sociology Optional Strategy Session with AIR 10 Ujjwal Priyank Click Here to register →
- Researchers from IIT Hyderabad have achieved a sustained release of a drug known as Amphotericin B for up to 10 days.This drug can be used for treating kala-azar.
- This will also help in oral administration of kala-azar drug which currently has major challenges.
- Visceral leishmaniasis(VL) also known as kala-azar is the most severe form of leishmaniasis.The disease without any proper diagnosis and treatment has been associated with high fatality.
- The disease is caused by protozoan parasites of the Leishmania genus, which migrates to the internal organs such as the liver,spleen (hence “visceral”) and bone marrow.
- The signs and symptoms include fever, weight loss, fatigue, anemia and substantial swelling of the liver and spleen.
- Kala Azar is endemic to the Indian subcontinent primarily in four countries namely Bangladesh, Bhutan, India and Nepal.Further,India itself accounts for half the global burden of the disease.
- Under National Vector Borne Disease Control Programme(NVBDCP), Government of India is coordinating with endemic States to eliminate the disease.
